Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury

2008 ◽  
Vol 14 (6) ◽  
pp. 621-626 ◽  
Author(s):  
Wanja M Bernhardt ◽  
Kai-Uwe Eckardt
2019 ◽  
Vol 47 (8) ◽  
pp. 1041-1049 ◽  
Author(s):  
Arnaud Gacouin ◽  
Mathieu Lesouhaitier ◽  
Aurelien Frerou ◽  
Benoit Painvin ◽  
Florian Reizine ◽  
...  

Author(s):  
Mohammed Ahmed ◽  
Sean M. Bagshaw

Acute kidney injury (AKI) remains a challenging clinical problem for clinicians caring for critically-ill patients due largely to the paucity of specific therapeutic interventions aimed at mitigating poor outcome. Those patients most at risk for the development of AKI can often be identified by an assessment of demographic, clinical, diagnostic, and procedure-related factors couple with early and intensive bedside monitoring. Importantly, critically-ill patients are often exposed to multiple discrete risks that can accumulate during their course that can negatively impact not only the duration and severity of AKI, but also probability of recovery, and long-term functional decline and risk of development of chronic kidney disease. All critically-ill patients at risk of or with milder forms of AKI should have support individualized. A clear understanding of the scope, complexity, and general principals of prevention and management of AKI are indispensable in the care of these patients and will discussed in this chapter.


2018 ◽  
Vol 10 (8) ◽  
pp. 1
Author(s):  
Juan Pedro Macias Pingarrón

El 12 de enero de 2018, el Comité de evaluación de riesgos de farmacovigilancia de la EMA (PRAC) recomendó la suspensión de HES del mercado europeo. Tras la evaluación de los datos de utilización de los medicamentos que contienen hidroxetil-almidón en diversos países europeos, el PRAC ha concluido que las medidas de minimización de riesgos introducidas en 2013 no han sido suficientemente efectivas. Por ello, ha recomendado la suspensión de la autorización de comercialización de los medicamentos con hidroxietil-almidón en la Unión Europea (UE). Los asistentes a la reunión de expertos ad-hoc de la EMA celebrada en Londres el 18 de diciembre de 2017, creen firmemente que la recomendación de la EMA de suspender HES no está fundamentada científicamente y es potencialmente peligrosa para los pacientes. ABSTRACT In January 2018, EMA’s safety committee PRAC recommended suspending the marketing authorisations of these medicines because they continued to be used in critically ill patients and patients with sepsis despite restrictions introduced in 2013 due to the risk of kidney injury and death in these patients. The CMDh agreed with the PRAC’s assessment of the serious risks in critically ill patients and patients with sepsis. However, the CMDh gave further consideration to the place of HES in the clinical practice of some countries, noted that previous risk minimisation measures had some effect, and considered that a combination of new risk minimisation measures would effectively ensure that HES solutions are not used in patients at risk.  


Sign in / Sign up

Export Citation Format

Share Document